Literature DB >> 27941112

Antisynthetase syndrome (ASS) presenting as acute respiratory distress syndrome (ARDS) in a patient without myositis features.

Venkat Kiran Kanchustambham1, Swetha Saladi1, Sarah Mahmoudassaf1, Setu Patolia1.   

Abstract

A woman aged 61 years presented to the emergency room with a 1-week history of dyspnoea on exertion and dry cough. X-ray of the chest showed diffuse interstitial opacities and was started on antibiotics and furosemide, and despite these measures, patient's respiratory status worsened, prompting endotracheal intubation. CT of the chest showed diffuse bilateral ground glass opacities and underwent bronchoscope with trans-bronchial biopsy that showed chronic bronchitis. Pt was empirically started on intravenous steroids due to concerns for interstitial lung disease (ILD). Autoimmune work up was sent and underwent video-assisted thoracoscopic surgery-guided biopsy of the lung that showed non-specific interstitial pattern with fibrosis. The patient was diagnosed as having antisynthetase syndrome with pulmonary involvement (ILD) as the cause of her acute respiratory failure. Azathioprine was started as steroid-sparing agent and was weaned off the ventilator to a tracheostomy collar and discharged to long-term rehabilitation centre. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27941112      PMCID: PMC5174888          DOI: 10.1136/bcr-2016-217624

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody.

Authors:  M Tomsic; F Sifrer
Journal:  Wien Klin Wochenschr       Date:  2000-08-25       Impact factor: 1.704

2.  Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Authors:  Sotiris C Plastiras; Fotini C Soliotis; Panayiotis Vlachoyiannopoulos; George E Tzelepis
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

3.  [Acute respiratory distress syndrome as the presenting manifestation of an antisynthetase syndrome].

Authors:  D Fagedet; S Bernard; B Colombe; A Bosseray; A Baudet; L Bouillet; C Massot
Journal:  Rev Med Interne       Date:  2008-10-30       Impact factor: 0.728

4.  Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis.

Authors:  A W Friedman; I N Targoff; F C Arnett
Journal:  Semin Arthritis Rheum       Date:  1996-08       Impact factor: 5.532

Review 5.  Antisynthetase syndrome.

Authors:  Elena Katzap; Maria-Louise Barilla-LaBarca; Galina Marder
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

6.  Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus.

Authors:  S Guglielmi; T M Merz; M Gugger; C Suter; L P Nicod
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

7.  A patient with antihistidyl-tRNA synthetase positive polymyositis presenting as acute respiratory distress syndrome.

Authors:  Riccardo Polosa; Cosimo Di Mauro; Barbaro Spampinato; Luigi Castelli; Giuseppe D'Amico; Cristopher J Edwards; Cristina Russo
Journal:  J Clin Rheumatol       Date:  2008-08       Impact factor: 3.517

8.  Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody.

Authors:  Kosuke Kashiwabara; Kosuke Ota
Journal:  Intern Med       Date:  2002-07       Impact factor: 1.271

9.  Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; P Y Hatron; S Dominique; E Hachulla; A Janvresse; P Cherin; L Mouthon; O Vittecoq; J-F Menard; F Jouen
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-05       Impact factor: 4.794

10.  Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.

Authors:  I Tillie-Leblond; M Wislez; D Valeyre; B Crestani; A Rabbat; D Israel-Biet; M Humbert; L J Couderc; B Wallaert; J Cadranel
Journal:  Thorax       Date:  2007-06-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.